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Abstract 
 
The aim of this article is to describe the process, evaluation criteria and possible outcomes of 
decision-making for new drugs listed in the Hong Kong Hospital Authority Drug Formulary 
in comparison to the health technology assessment (HTA) policy overseas. Details of 
decision-making processes including the new drug listing submission, Drug Advisory 
Committee (DAC) meeting, and procedures prior to and following the meeting, were 
extracted from the official Hong Kong Hospital Authority drug formulary management 
website and manual. Publicly-available information related to the new drug decision-making 
process for five HTA agencies (the National Institute of Health and Care Excellence (NICE), 
the Scottish Medicines Consortium (SMC), the Australia Pharmaceutical Benefits Advisory 
Committee (PBAC), the Canadian Agency for Drugs and Technologies in Health (CADTH), 
and the New Zealand Pharmaceutical Management Agency (PHARMAC)) were reviewed 
and retrieved from official documents from public domains. The DAC is in charge of 
systemically and critically appraising new drugs before they are listed on the formulary, 
reviewing submitted applications, and making the decision to list the drug based on scientific 
evidence to which safety, efficacy and cost-effectiveness are the primary considerations. 
When compared with other HTA agencies, transparency of the decision-making process of 
the DAC, the relevance of clinical and health economic evidence, and the lack of health 
economic and methodological input of submissions are the major challenges to the new-drug 
listing policy in Hong Kong. Despite these challenges, this review provides suggestions for 
the establishment of a more transparent, credible, and evidence-based decision-making 
process in the Hong Kong Hospital Authority Drug Formulary. Proposals for improvement in 
the listing of new drugs in the formulary should be a priority of healthcare reforms.  
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Key Points for Decision-Makers 
 Improvement of the transparency of decision-making processes, including disclosure 
of the rules governing decision in terms of cost-effectiveness, conflict-of-interest 
declaration from those initiating submissions, and the engagement of key external 
stakeholders, would support the credibility and accountability of decisions made by 
the Drug Advisory Committee. 
 Detailed information on costs of new and alternative drugs, healthcare services due to 
the uptake of new drugs and other condition-related health care services, as well as 
other important aspects within the budget-impact analysis framework would allow the 
Drug Advisory Committee to better understand the value of new and alternative 
drugs. 
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Manuscript Text 
 
Introduction 
 
Due to the necessity of efficiently allocating resources under fixed budgetary control, there 
has been increase in demand for a systematic process of health technology assessment (HTA), 
placing emphasis on the value of emerging and conventional drugs. Drug appraisal and the 
review process involves an initial assessment of clinical evidence and health economic 
evidence for certain developed countries, which leads to recommendations or the decision to 
reimburse new drugs based on appraisal of the best-available evidence[1]. This approach to 
review has been adopted in the Hong Kong drug listing formulary system and new drug 
reimbursement systems in many developed commonwealth countries[2-5] and some Asian 
countries such as South Korea[6-8], Japan[9], Thailand[8], and Malaysia[10]. 
Recommendations for new drugs may vary from country to country because of the 
differences in jurisdictions and decision-making processes[11]. 
 
In Hong Kong, the Drug Advisory Committee (DAC) evaluates and advises on new drugs to 
be included in listing on Hospital Authority Drug Formulary[12], the largest public healthcare 
service provider. New and existing drugs approved by the DAC are included in the Hospital 
Authority Drug Formulary which was established in July 2005. Missions of the Drug 
Formulary include the standardization of drug and drug-use policies in affiliated hospitals and 
clinics across regional clusters, and ensuring equal access of patients to cost-effective drugs, 
the safety and efficacy of which are proven. In the past decade, prevailing drugs listed on the 
drug formulary has rapidly expanded with the increased budget allocated to new drugs that 
patients can access. In response to intense public scrutiny over the decisions of new drugs 
listed on the Drug Formulary, the Hospital Authority drug formulary management system was 
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reformed in 2015. However, the drug review process challenged due to its lack of 
transparency to members of the public and scientific documentation as the base for the 
decisions made[13]. 
 
The purpose of this paper is to describe the process, evaluation criteria and possible outcomes 
of the decision for new drugs to be listed in the Hong Kong Hospital Authority Drug 
Formulary. This review summarizes the decision-making trajectory from submission to final 
outcomes within the context of Hong Kong in comparison to existing policies of countries 
overseas that adopt the HTA for submission of new-drug reimbursement. Hence, this review 
outlines the challenges and suggestions for the establishment of a more transparent, credible, 
and evidence-based decision-making process in Hong Kong. 
 
Method 
 
Details of decision-making processes including submissions for new drug listings, DAC 
meetings, and procedures prior to and following the meeting, were extracted from the official 
Hong Kong Hospital Authority drug formulary management website[12] and manual[14]. To 
compare HTA policy in Hong Kong to overseas commonwealth countries, information related 
to the new drug decision-making process for HTA agencies with a centralized drug review 
process[1] were reviewed and retrieved from official English guidelines published on the 
website of advisory bodies. Decision-making processes of neighboring Asian countries such 
as China[8, 15, 16], South Korea[6-8], Japan[9], Thailand[8] and Malaysia[10] were only 
reported in published literature but not on the official advisory body websites. Therefore, 
these countries are not included in the comparisons. All publicly-available information related 
to the new drug decision-making process of the England National Institute of Health and Care 
Excellence (NICE)[2], the Scotland Scottish Medicines Consortium (SMC)[3], the Australia 
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Pharmaceutical Benefits Advisory Committee (PBAC)[4], the Canadian Agency for Drugs 
and Technologies in Health (CADTH) Canadian Drug Expert Committee(CDEC)[5], and the 
New Zealand Pharmaceutical Management Agency (PHARMAC) Pharmacology and 
Therapeutics Advisory Committee (PTAC) were assessed, reviewed and synthesized by the 
author (CW). Information was extracted in May 2017.  
 
Results 
 
Current New Drug Listing Policy in Hong Kong 
 
Prior to 2013 the Drug Utilization Review Committee (DURC) was the advisory body 
responsible for appraising new and existing drugs for inclusion into the formulary. Due to 
fundamental changes in governance structure in 2013, the Drug Management Committee 
(DMC) was established to supersede the former Drug Utilization Review Committee 
(DURC), and is supported by five functional sub-committees: the Drug Advisory Committee 
(DAC), the Drug Formulary Committee, the Drug Selection Committee, the Medication 
Safety Committee, and the Cluster Drug and Therapeutics Committees. In 2015, the Hospital 
Authority published the Drug Formulary Management Manual to explicitly describe overall 
formulary management in terms of: 1) the governance structure of drug management and the 
composition of the five functional sub-committees, 2) mechanism, principles, the decision-
making process of new drugs listed on the Formulary, and 3) consultation, engagement and 
participation of internal and external stakeholders. According to the latest version of the 
management manual[14], the sub-committee of the DAC is in charge of systematically and 
critically appraising new drugs for listing on the formulary, reviewing submitted applications, 
and making the decision to list drugs based on scientific evidence to which safety, efficacy 
and cost-effectiveness are the primary considerations. Notably, new drug applications are 
Page 10 of 20 
only accepted through the Hospital Authority clinicians, not through pharmaceutical 
companies or clinicians outside the Hospital Authority. Other practical considerations include 
referring to international recommendations and practices for drugs already assessed, 
innovation and advanced technology to which a new drug is expected to bring significant 
advantages over similar, existing drugs on the formulary, disease state, patients’ needs, patient 
compliance, quality of life, clinical effectiveness of a new drug in terms of the use of the drug 
in the local population, and suggestions and feedback from relevant patient group and expert 
panels.  
 
DAC meetings are held four times per year in January, April, July and October. New drug 
submissions received three months prior to a DAC meeting are scheduled to be reviewed and 
thus listed on the agenda of the meeting to come. In brief, prerequisite information for 
submissions includes general information on the new drug, the target population (proposed 
location of treatment, administration criteria, exit criteria and indication for this new drug), 
choice of main comparators (existing alternatives already available in the Hospital Authority), 
clinical evidence and its level (benefits in term of efficacy, safety issues, and other benefits), 
international guidelines and overseas reimbursement assessment status, and cost comparisons 
of the new drug and similar ones already available and budget impact mainly about hospital 
expenditure, specifically medicine expenditure rather than the total costs including 
ambulatory care. Detailed information required for the submission form for a new drug is 
shown in the Electronic Supplementary Material - Appendix A. The decision on new drugs is 
made during the following DAC meeting, and is made publicly available within 3 weeks.  
 
Following the DAC meeting, the decision on the submissions of each new drug falls into one 
of the following categories: 1) Approval for use as a ‘General Drug’ which is made available 
for general use by patients with relevant clinical conditions under the Hospital Authority; 2) 
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Approval for use as a ‘Special Drug’ with restriction on specific specialty, subject to the 
prescriber or clinical condition; 3) Approval for use as ‘Self-financed Items’ with a safety net 
provided through the Samaritan Fund or the Community Care Fund Medical Assistance 
Programme; 4) Pending; or 5) Rejection. The third category is not covered by standard fees 
and charges in public hospitals and clinics but by patients who require these drugs and can 
afford the costs to purchase them at their own expense. A safety net is provided through 
relevant funds to subsidize the costs of drugs for patients who have financial difficulties. In 
cases when the DAC solicits further information and advice from expert opinions on clinical 
guidelines or protocols related to drugs before making a decision, the recommendation is 
noted as ‘pending’. Meanwhile, relevant specialties from an expert panel are invited to 
submit recommendations. Decisions are made publicly available on the designated website of 
the formulary within 3 weeks following the DAC meetings, accompanied by a list of 
references that were considered during decision-making process. Although the primary 
reason for rejection is made public, reasons for acceptance and approval of new drugs are not 
available. Reasons for rejection are primarily categorized as ‘insufficient justification of the 
treatment’s cost in relation to its benefits’, ‘alternative(s) available in Hospital Authority 
Drug Formulary with comparable benefits’, ‘insufficient evidence to demonstrate clinical 
outcome benefits’, ‘lack of high quality level of evidence to demonstrate its efficacy’, 
‘insufficient evidence to address safety concern’, and ‘insufficient evidence to demonstrate 
improvement in quality of life’, etc.  
 
Based on the established mechanism, a total of 164 new drugs were listed on the drug 
formulary between July 2005 and March 2014[17]. However, the transparency, relevance and 
consistency of the current drug listing policy are subject major challenges such as the 
comparison to the new drug reimbursement decision-making process of the five HTA 
agencies and the international good practice guidelines for conducting budget-impact 
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analysis[18-20]. Table 1 summarizes the decision-making process of new drug submissions in 
Hong Kong, England and Scotland (in the UK), Australia, Canada, and New Zealand.  
 
Transparency of the decision-making process 
 
A closed committee meeting format is adopted by the DAC. In the SMC, PBAC, CADTH 
and PHARMAC meetings, only committee members are eligible to attend but non-committee 
members may be invited to attend as observers. In contrast, NICE technology appraisal 
meetings are semi-open for members of the public to attend and observe the introduction and 
presentation sessions. Moreover, all DAC members, except for the Chairperson who must 
disclose his/her name and position, remain anonymous on the formulary management 
website. Unlike the practice in Hong Kong, the identity of each committee member overseas 
is made publicly available.   
 
All available evidence considered relevant to the decision-making process is unknown to 
external stakeholders including patient groups, pharmaceutical companies, and members of 
the public, however it is made known to groups or hospital Drug and Therapeutics 
Committees which comprise of internal stakeholders. For overseas HTA agencies, 
commercially-sensitive information such as confidential discounts due to risk sharing 
arrangements[21] and managed entry agreements[22] as well as drug tender price[23] are 
coloured out in publicly-available documents. 
 
Although patient groups are invited to provide suggestions and feedback prior to the meeting, 
neither members of the public nor pharmaceutical companies are represented during the 
meeting or are involved in the decision-making process. A similar stakeholder arrangement is 
found in Canada where representatives of the patient group and manufacturer are not 
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permitted to attend the CADTH meetings. The Patient and Clinical Engagement (PACE) 
Group has been established to give patient groups and clinicians a stronger voice in the 
SMC’s decisions of new medicines for end-of-life and very rare conditions[24].  
 
Following the DAC meeting, there is no final decision report on the drug appraisal published 
or relevant DAC meeting minutes detailing evidence regarding the effectiveness of the 
treatment, safety concerns and cost-effectiveness, or comments from patient groups or expert 
panels. Compared to past submissions to the NICE[25] and the SMC[26], there is no 
quantitative or composite weighting assigned to each factor when making the decision 
reimbursing a new drug. However, health economic evidence concerning the outcomes of the 
cost-effectiveness analysis is one of the evaluation criteria for making the decision (Table 1). 
The factors that heavily influence past decisions of the DAC and individual members, i.e. the 
approval and rejection of new drugs, cannot be ascertained. In DAC meetings between 
October 2015 and July 2016, 25 submissions of new drugs were rejected[12]. The most 
frequent reason for rejections given was ‘Alternative(s) available in the HADF with 
comparable benefits’ (10; 40%) followed by ‘Insufficient justification of the treatment’s cost 
in relation to its benefits’ (6; 24%). Around one-fourth of rejections were due to the latter 
reason, reflecting a barrier of submission initiators to justify the value and economic evidence 
of the submission of a new drug. The central rule of decision-making as to how the drug is 
considered cost-effective is not transparent to external stakeholders such as patient groups, 
academics or pharmaceutical companies. The experience of European countries involved 
submitting physicians to establish a ‘Wise List’ of new medicines jointly recommended for 
primary and hospital care, which consequently increased the approval rates of prescribed 
medicines that are recommended in the ‘Wise List’[27, 28]. 
 
Clinical evidence 
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Clinical evidence such as efficacy and safety of a new drug compared to similar ones that are 
already available is a key consideration. It is mandatory to list the efficacy and safety issues 
of a new drug compared to existing ones when submitting for approval (Appendix A). 
Claimed benefits must be clearly referred to supporting documents that detail information and 
data from clinical trials published as full articles. Clinical evidence of the highest level is 
considered. Mounting evidence from meta-analysis or network meta-analysis of randomized 
controlled trials is desirable. Head-to-head direct comparative randomized trials are preferred 
over indirect comparisons and placebo-controlled trials. Despite taking leading clinical 
evidence into account, this approach largely relies on the information submitted by the 
initiators, through which conflicts of interest may occur. Although the evidence submitted 
may be incomplete or biased, a detailed report must also be prepared by the Chief 
Pharmacist’s Office. 
 
Health economic evidence 
 
‘Cost-effectiveness’ is one of three principal considerations for evaluating new drug listing 
applications. In the new drug submission form, only information related to occurrence of the 
disease (such as in relation to the population size) and the impact of the drug listing on the 
formulary on the Hospital Authority budget with possible savings are mandatory for 
submission (Appendix A). In principle, ‘cost-effectiveness’ and ‘budget impact’ are 
conceptually different. When assessing health economic evidence of submissions, the current 
policy is to adopt the ‘budget impact’ and ‘cost consequence’ approach in term of whether the 
new drug will impose a direct monetary consequence or significantly higher direct medical 
costs from the perspective of the Hospital Authority as a justification of the affordability or 
‘willingness-to-pay’ of the Hospital Authority healthcare services for the clinical benefit of 
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the drug. Based on the experience abroad, the budget impact analysis together with the cost-
effectiveness analysis have a significant impact on decision-making.  
 
Although a budget impact analysis is essential for making the decision to list a new drug[29], 
current input and data sources required in the submission form are insufficient to estimate the 
budget impact from the perspective of the Hospital Authority. Reports of the Society for 
Pharmacoeconomics and Outcomes Research (ISPOR)[18, 19] on good research practices 
have made general recommendations on the input and data sources for the budget impact 
analysis which is informed not only by costs of new and alternative drugs but also costs of 
other condition-related healthcare services provided by the Hospital Authority. The cost 
comparison is limited to the purchasing costs of new and alternative drugs but direct costs of 
monitoring and surveillance associated with new drug are seldom considered. Thus, the 
introduction of new drugs may alter the use of other condition-related healthcare services in 
terms of physician visits, emergency visits, hospitalization, laboratory testing, diagnostic and 
surgical procedures, the result changes of symptoms, duration and progression of the disease, 
or complications associated with the condition. Several aspects such as the time horizon, time 
dependency and discounts, and an uncertainty and scenario analysis, within budget impact 
analysis framework are not taken into consideration. Furthermore, a Canadian budget impact 
analyses guideline[20] provided recommendations regarding the analytic framework, inputs 
and data sources, and reporting format of the budget-impact analysis evidence submitted to 
the CADTH. However, the data input and sources of the budget impact analysis required in 
the submission form are not required to adhere to the key characteristics for good practices in 
the international budget-impact analysis guidelines. 
 
Classical health economics literature[30, 31] defined three major forms of health economic 
evaluation: a cost-benefit analysis, cost-effectiveness analysis, or cost-utility analysis. A cost-
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minimization analysis is considered a subcategory of a cost-effectiveness analysis. While the 
concept of ‘cost-minimization’ is easy to comprehend and thus disseminate to both 
professional and public audiences, it can only be used under the assumption of equal 
treatment and the effectiveness of the new and existing drugs. There have been major debates 
and criticism [32, 33] on the use of the cost-minimization analysis because of its biased 
estimation of uncertainty, leading to a higher chance of making the wrong decision. 
Furthermore, new drugs are, in general, more expensive than existing ones. Clearly, one 
possible consequence is the inclusion of a cost-saving drug which is less effective than ones 
that already exist. Unless non-inferiority or equal-effectiveness withstands, the cost-
minimization analysis is a less appropriate approach than the other three methods of analysis 
(i.e. cost-effectiveness analysis, cost-utility analysis, and cost-benefit analysis) that account 
for both costs and effectiveness associated with new and existing drugs. A calculation of the 
incremental cost-effectiveness ratio (ICER) that explicitly demonstrates the clinical benefits 
at the expense of additional costs is not required by the DAC for the evaluation of a new 
drug. However, an ICER value of the new drug versus the main competitor drugs is an 
important attribute and a preferred cost-effectiveness measure for decision making in the UK, 
Australia, and Canada. For instance, in England, the decision-making process in the NICE 
relies on the ICER value of less than the formal ICER threshold of £20,000-30,000 
(US$21,880-32,823) per quality-adjusted life-year (QALY) for being normally accepted for 
reimbursement[2], and less than £50,000 (US$54,700) per QALY for new cancer drugs 
extending life expectancy towards the end of the patient’s life. An empirical estimate of the 
ICER threshold based on the effects of changes in NHS expenditure on patients’ health was 
likely to be £12,936 (US$14,152) per QALY[34]. From 1991 to 1996, based on submissions 
to the PBAC, the ICER threshold for recommending a new drug for listing by PBS ranged 
from AUS$42,000-76,000 (US$31,168-56,400) per life-year[35]. In Hong Kong, the potential 
ICER threshold is US$61,600 per effectiveness unit for what was considered to be a cost-
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effective cancer screening program for recommendation[36]. Whilst the DAC does not have a 
preferred cost-effectiveness threshold or a formal ICER threshold, the input of cost-
comparison and budget-impact values contributes to the conclusion of whether the new drug 
is cost-saving or simply costs the Hospital Authority, as opposed to a conclusion of whether 
the new drug is cost-effective compared to existing drugs. 
 
Health economic and methodological data on submissions 
 
In overseas countries, health economists and methodologists in review committees and 
independent parties serve the role of reviewing health economic and other technical aspects 
of submissions in terms of long-term model simulation, budget impact and cost-effectiveness 
of a new drug versus existing ones. Representatives with expertise in health economics, 
mainly academics, are members of the NICE Technology Appraisals Committee and SMC in 
the UK, the PBAC in Australia, and the CADTH in Canada. In the UK, submissions are 
independently reviewed by the Evidence Review Group and New Drugs Committee, 
specifically providing health economic and methodological input prior to the review by the 
Technology Appraisals Committees and SMC, respectively. Methodologists and health 
economists are not part of the PTAC in New Zealand but PHARMAC contracts health 
economists to prepare health economic analyses.  
 
The DAC comprises of 12 members[37] including administrators, pharmacists, academics, 
and clinical experts from different specialties (medicine, surgery, orthopaedics and 
traumatology, paediatrics, psychiatry, oncology, anaesthesiology and pain medicine, 
dermatology, infectious disease, family medicine, obstetrics and gynaecology, 
ophthalmology, ear, nose and throat), providing balanced views on the clinical effectiveness 
and safety of drugs assessed. However, the composition of the DAC and the expert panel 
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lacks input from health economists. 
 
Discussions and Conclusions 
 
This paper reviews the decision-making process of new drugs listed on the formulary in Hong 
Kong, and compares it to the HTA process of new drug reimbursement overseas. 
Discrepancies in the decision-making process from several countries are presented in this 
review. There is no perfect new drug reimbursement system anywhere in the world, and it is 
unrealistic to transfer a whole new system to Hong Kong. Nevertheless, lessons from 
overseas countries provide valuable insights into the Hospital Authority, which aims to 
establish transparent, credible, objective, and robust decision-making in the formulary 
management system. Firstly, improvement in the transparency of the decision-making 
process, including the disclosure of the rules of making decisions in terms of cost-
effectiveness, declarations of conflicts of interest from submitters, and engagement of key 
external stakeholders would support the credibility and accountability of the decisions made 
by the DAC. Secondly, the adoption of a budget-impact analysis framework from 
international guidelines would enhance the standardization and improve the quality of 
budget-impact analysis[38], and thus present a better picture of the budget impact to health-
policy makers. Detailed information on costs of new and alternative drugs and healthcare 
services due to the uptake of new drugs, and other condition-related healthcare services and 
important aspects within the framework of budget-impact analysis would allow the DAC to 
better understand the value of new and alternative drugs. Thirdly, a cost-effectiveness 
measure, expressed in either ICER or a net monetary benefit, should be presented in the 
submission to determine whether a new drug is considered cost-effective. Finally, health 
economists and methodologists are required to review the calculations regardless of whether 
the cost-effectiveness analysis is based on local or overseas data. The DAC should consider 
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including members with expertise in health economics on the expert panels.  
 
In summary, there are a number of challenges facing the Hong Kong Hospital Authority 
regarding the Drug Formulary. Proposals for the improvement of the listing of new drugs in 
the formulary should be a priority when implementing healthcare reforms. 
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Table 1. Comparisons of New Drug Submission and Decision-making Process in Hong Kong and Overseas Countries 
  Overseas Countries 
Hong Kong UK England  UK Scotland  Australia Canada New Zealand 
Drug listing Hospital Authority NHS England NHS Scotland Pharmaceutical Benefits 
Scheme (PBS) 
Canada’s public drug plans, 
except for Quebec 
New Zealand 
pharmaceutical schedule 
Advisory body 
and review 
committee 
Drug Advisory Committee 
(DAC) 
NICE Technology Appraisals 
committees (TAC) 
Scottish Medicines 
Consortium (SMC) 
Pharmaceutical Benefits 
Advisory Committee 
(PBAC) 
CADTH Canadian Drug Expert 
Committee (CDEC) 
PHARMAC Pharmacology 
and Therapeutics Advisory 
Committee (PTAC) 
Composition of 
review committee 
members 
12 members including Hospital 
Authority pharmaceutical 
service management corporate 
director, chief pharmacist, 
clinicians from different 
specialties, and academics in 
healthcare-related disciplines 
from local universities 
96 members with 
representatives of the NHS, 
patient and carer organisations, 
academia, and pharmaceutical 
and medical devices industries, 
evenly across 4 individual 
committees 
Representatives of Area Drugs 
and Therapeutics Committee 
leads from each heath board in 
Scotland 
Representatives of medical 
practitioners, pharmacists, 
patient support group, 
health economists, and 
company  
14 members with 
representatives of technical 
experts with qualifications as 
physician, pharmacist, 
economist, or other health 
professionals, and lay public 
Senior health practitioners 
nominated by professional 
medical bodies 
Initiator Hospital Authority clinicians  Manufacturers Manufacturers Manufacturers Manufacturers Pharmaceutical suppliers, 
health professionals, patients 
and consumers 
Evaluation criteria Three principal criteria (safety, 
efficacy and cost-
effectiveness), International 
recommendations and 
practices, advance in 
technology, disease state, 
patient compliance, quality of 
life, actual experience in use of 
drugs, and views of 
professionals and patient 
groups 
Clinical and cost effectiveness 
of treatments for use within the 
NHS 
Clinical and cost effectiveness 
of treatments 
Comparative health gain, 
comparative cost-
effectiveness, patient 
affordability in the absence 
of PBS subsidy, and 
predicted use in practice 
and financial implications 
Patient group input, safety, 
efficacy, effectiveness, 
therapeutic advantages and 
disadvantages, cost and cost-
effectiveness of new drug 
relative to current accepted 
therapy 
Health needs, availability 
and suitability of existing 
medicines, clinical benefits 
and risks of pharmaceuticals,  
cost-effectiveness, budgetary 
impact, direct cost to health 
service users, Government’s 
priorities for health funding, 
and other criteria 
Independent 
assessors 
Expert panel Evidence Review Group New Drugs Committee Economics Sub-Committee 
and Drug Utilisation Sub-
Committee 
Common Drug Review team PTAC Subcommittees in 
specialist areas 
Patient and carer 
group engagement 
Notification of meeting agenda 
to patient group. Report 
suggestions and feedback 
received from patient group 
during the meeting. No 
engagement in carer group 
Invitation of patient group or 
their carer to submit narrative 
summaries about disease and 
treatment experience, 
acceptability of, preferences 
for and expectations about 
treatment 
Invitation of patient groups to 
submit experiences of patients, 
their families and carers, 
advantages and disadvantages 
of new drugs.  
 
A Patient and Clinical 
Engagement (PACE) Group to 
give patient groups a stronger 
voice in decisions of new 
medicines for end-of-life and 
very rare conditions 
Invitation of patient groups 
to comment benefits and 
harms of new drug. No 
engagement in carer group 
Invitation of patient input to 
provide experiences of 
condition, currently available 
treatments and new drug, and 
expectations of for new drug 
No engagement in patient 
and carer group but patient 
and carer group may be a 
initiator 
Meeting       
Running Title: Hong Kong Hospital Authority Drug Formulary 
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  Overseas Countries 
Hong Kong UK England  UK Scotland  Australia Canada New Zealand 
Format and 
attendance 
Closed; DAC Members Public & Private; TAC 
Members, patient experts, 
clinical specialists, 
commissioning experts 
(Evidence Review Group), and 
public observers 
Public; SMC Members, 
invited experts, industry, 
patient group, public observers 
Closed; PBAC Members 
and other attendees by 
invitation only (sponsors, 
clinical experts, patient 
groups) 
Closed; CDEC Members and 
other attendees by invitation 
only (health ministry officials, 
specialist experts, contracted 
external reviewers, and invited 
observers). Manufacturers and 
patients are not entitled to 
attend. 
Closed; PTAC members, 
secretary, observers 
Quorum 50% of committee membership 50% of committee membership 1/3 of committee membership Not available 66% of committee membership Six members 
Voting Consensus of committee 
members present normally. 
Voting in exceptional cases 
Consensus of committee 
members present normally. 
Voting in exceptional cases 
Decision based on a majority 
vote 
Not available Decision based on a majority 
vote 
Consensus of committee 
members present normally. 
Voting if consensus cannot 
be achieved 
Preferred cost-
effectiveness 
measure 
Not available ICER in term of cost per 
QALY gain 
ICER in term of cost per 
QALY gain 
ICER; Unspecified 
effectiveness unit  
ICER; Unspecified 
effectiveness unit 
Cost-utility analysis as 
recommended economy 
analysis. ICER in term of 
cost per QALY gain 
Decision making 
approach 
Not available <£20,000 per QALY; £20,000-
30,000 per QALY plus four 
criteria satisfied (degree of 
uncertainty around the ICER, 
adequacy of health-related 
quality of life captured, 
innovation, and relation to 
non-health objectives of NHS); 
<£50,000 per QALY for end-
of-life drugs 
<£20,000 per QALY; £20,000-
30,000 per QALY plus 
significant benefits over 
existing treatments 
Not available Not available Not available 
Decision 
categories 
Approval for use as ‘General 
Drug’; Approval for use as 
‘Special Drug’; Self-financed 
Items; Pending; Rejection 
Recommended; Optimised; 
Only in research; Not 
recommended 
Accepted for use; Accepted 
for restricted use; Not 
recommended for use 
Recommended; Deferrals 
of a recommendation; Not 
recommended  
List; List with clinical criteria 
and/or conditions; Do not list at 
the submitted price; Do not list 
Recommended; Defer a final 
recommendation; Not 
recommended 
Post-meeting       
Decision publicly 
available 
Within 3 weeks after the 
meeting 
About 3 months after the 
meeting 
About four weeks after the 
meeting 
6 weeks after the meeting After an embargo period of 10-
30 business days 
Not available 
Report on 
decision publicly 
available 
Not available Draft minutes are submitted to 
the next meeting for approval. 
Within 20 working days of 
approval 
Not available 16-18 weeks after the 
meeting 
Same day as final decision Not available 
Implementation of 
approved drugs 
listed 
Around 3 months after the 
meeting 
Within 3 months of decision 
published 
Not available After the price agreement 
and budget-impact 
evaluation 
Not available Not available 
Appeal 
mechanism 
No Within 15 working days of 
final draft guidance published 
Yes (but deadline of appeal 
unknown) 
Within 90 days of decision 
made 
A procedural review Request 
submitted within 10 working 
days of final recommendation 
published 
No 
NHS = National Health Services; NICE = National Institute of Health and Care Excellence; PBS = Pharmaceutical Benefits Scheme; PBAC = Pharmaceutical Benefits Advisory Committee; CADTH = Canadian 
Agency for Drugs and Technologies in Health; CDEC = Canadian Drug Expert Committee; DAC = Drug Advisory Committee; PHARMAC = Pharmaceutical Management Agency; PTAC = Pharmacology and 
Therapeutics Advisory Committee; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-year; TAC = Technology Appraisals committees; PACE = Patient and Clinical Engagement 
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HA Drug Advisory Committee
New Drug Submission Form
An application can be submitted, via Cluster / Hospital DTC, for consideration of listing 
on the HA Drug Formulary if the concerned drug entity or indication fulfills the following 
criteria: 
a)  It is indicated for prevention or treatment of conditions which are not covered by 
drugs in the existing HA Drug Formulary; 
b)  It has an advantage in terms of efficacy and adverse effects over agents in the 
existing HA Drug Formulary for the same indication; or
c)  It is equivalent in terms of safety and efficacy as compared to existing agents in 
the HA Drug Formulary for the same indication and of lower treatment costs.
Please complete ALL sections and attach relevant supporting documents in order to 
facilitate the evaluation. Incomplete information may lead to delay in the submission 
process.
FOR INTERNAL USE ONLY
DAC Ref. No.: Date received:
Appendix IV DAC New Drug Submission Form 
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1. GENERAL INFORMATION
1.1 Submitting hospital:
1.2 Name of drug: Generic (Trade)
1.3 Name of manufacturer / supplier:
1.4 Strength & form:
1.5 Cost (per unit):
1.6 Current formulary status of this drug:
	 ☐ Non-Formulary use – SFI
	 ☐ Non-Formulary use – Hospital-funded
	 ☐ Sample use
1.7 Proposed financing method:
	 ☐ Hospital-funded
	 ☐ SFI
1.8 Status of application:
1.8.1 Approved by hospital DTC:
1.8.2 Date of DTC meeting:
☐ Yes
☐ pending
1.9 Applying doctor (name, rank, specialty)
Name:
Rank:
Specialty:
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2. PROPOSED PLACE IN THERAPY IF INTRODUCED INTO HADF
2.1  Licensed indication(s) of this new drug in HK   
(specific for this submission)
e.g. Erosive Esophagitis
2.2 Worldwide registration status for this indication (if known) 
 (e.g. registration status and month/year in Australia, Canada, EU, US)
e.g.
2.3 Natural History of the disease
 (e.g. survival time, time to progression of the disease)
e.g.  The median survival for patients with the disease ranges from approximately 
2–11 years depending on risk stratification; the median survival time for 
patients with intermediate–2–risk is 4 years and 2 years for patients with high-
risk disease.
Country Dosage Indication Approval 
Date
Hong Kong 30mg capsules
60mg capsules
Erosive Esophagitis Nov 2010
USA 30mg capsules
60mg capsules
Erosive Esophagitis
Maintenance of healed EE
Symptomatic non-erosive GERD
(no need to list these indications 
which are unlicensed in HK/not 
for this application
Jan 2009
May 2005
May 2005
Australia 30mg capsules
60mg capsules
Erosive Esophagitis
Maintenance of healed EE
Symptomatic non-erosive GERD
Jul 2010
Apr 2006
Apr 2006
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2.4 Existing treatment protocol for this disease in HA
  (Please list out all existing treatment alternatives, dose regimens and   
sequence of use)
2.4.1  Existing treatment alternatives with dose regimens   
(Note:- alternatives must be available in HA):
  e.g.
  Insulin Lispro – individualised dose
  Insulin Aspart – individualised dose
  e.g.
  sitagliptin 5mg once daily
  vildagliptin 50mg-100mg once daily
2.4.2 Sequence of use:
  e.g.
  In patients with T2DM
  Step 1: Initiate with metformin
  Step 2: After failed the optimal doses of metformin, add a sulphylurea
  Step 3:  After failed the optimal doses of metformin and a sulphonylurea, 
add DPP-4
  Step 4: After failed all oral anti-diabetic agents, give insulin
2.5 Proposed place in therapy of this new drug in relation to 2.4.2
  (Proposed treatment protocol or algorithm for this disease after introduction of 
this new drug)
 e.g.(1) IF NEW DRUG IS IN ADDITION TO EXISTING TREATMENT
 Use the new drug as an alternative to insulin:- 
 In patients with T2DM
 Step 1: Initiate with metformin
 Step 2: After failed the optimal doses of metformin, add a sulphylurea
 Step 3:  After failed the optimal doses of metformin and a sulphonylurea, 
add DPP-4
 Step 4: After failed all the above treatments, give Drug A (new drug)
 Step 5: After failed all the above treatments, give insulin
 e.g.(2) IF NEW DRUG IS AN ALTERNATIVE TO EXISTING TREATMENT
 e.g.  The new drug Insulin A is another option for existing short-acting insulin 
available in HA
 e.g. (3) IF THERE IS NO EXISTING ALTERNATIVE
 e.g.  Bosentan for pulmonary aterial hypertension NYHA/WHO Functional Class 
IV symptoms
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2.6 Treatment initiation and exit criteria for the new drug
2.6.1 Initiation criteria: 
  e.g. (1)  in patients refractory to the alternatives stated in Section 2.4.1
  e.g. (2)  patients who had received at least 1 prior course of chemotherapy 
and had disease progression or relapse since chemotherapy
2.6.2 Exit criteria: 
  e.g. (1)  patient not responding after 3 months of treatment
  e.g. (2)  Treatment will be terminated if the patient develops progressive 
disease or unmanageable toxicities
  e.g. (3)  discontinue if fail to achieve HbA1c<8% within 6-8 months
2.7 Proposed HA Drug Formulary Indication(s) for this new drug 
  (Please list out proposed indication wordings as would appear in MOE, each 
indication should be within 200 characters including punctuation marks and 
spacing)
  e.g.  Short-term treatment of moderate to severe atopic dermatitis in non-
immunocompromised patients unresponsive to other topical treatments 
or when those treatments are not advisable (total 177 characters)
2.8  Authorisation for prescribing this new drug for this indication   
(which specialty)
  e.g. Specialists: Derm / Paed
2.9 Proposed HA Drug Formulary status
 (General / Special / SFI)
  e.g. Special
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3.  SUMMARY OF BENEFITS OF THIS NEW DRUG OVER EXISTING 
OPTIONS LISTED IN SECTION 2.4
 (DETAILS TO BE PROVIDED IN SECTION 4)  
3.1 Benefit in Efficacy
  e.g. (1)  Median time to progression was significantly longer in patients 
receiving the new drug  compared to drug A [drug A must be currently 
available in HA] (14.3 months vs. 6 months, HR=0.34, p=0.001)
 e.g. (2)   The  percentage of 24-h heartburn-free days and night was significantly 
greater in patients receiving the new drug than placebo (69% vs. 15%, 
p=0.001)
 e.g. (3)  Improvement in symptom severity and overall quality of life were 
maintained over 6 month 
3.2 Benefit / Concerns in Safety Issues
 e.g. (1)  The new drug has lower incidence of EPS than both haloperidol (13% 
vs. 25%, p<0.001) and risperidone (17% vs. 22%, p=0.1), but a 
significantly higher increase in QT interval (7% vs. 0.5%, p<0.001) and 
a weight gain of 4.6kg over 1 year
 e.g. (2)  The new drug is well tolerated with an adverse event profile similar to 
that of placebo; however, the incidence of hypoglycemia was higher 
than existing alternatives listed in Section 2.4.1 (8% vs. 3%, p<0.001)
3.3 Other Benefit(s)
 e.g. (1)  Less drug-drug interaction than existing alternatives listed in Section 
2.4.1
 e.g. (2)  First drug in the class available in oral form, more convenient than the 
existing alternatives; more acceptable by patients
 e.g. (3)  The controlled released formulation improves compliance than the 
multiple dosing of the immediate-release formulation.
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4.  DETAILS ON CLAIMED BENEFIT(S) OF THIS NEW DRUG AS 
SUMMARISED IN SECTION 3
 •  All supporting documents MUST be clearly referred to
 • Do not include any data on unlicensed indication(s)
 •  Only provide the highest level of evidence for each individual claimed benefit 
listed in Section 3 
   (e.g. if efficacy has already been proven in phase III randomised-controlled 
trials, there is no need to provide evidence from placebo-controlled trials etc.)
 •  Only accept fully published clinical trials (no abstracts or posters)
4.1 Benefit in Efficacy
4.2 Benefit in Safety Issues
4.3 Other Benefit(s)
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5.  AVAILABLE INTERNATIONAL GUIDELINES AND OVERSEAS 
REIMBURSEMENT ASSESSMENT DOCUMENTS 
 (All supporting documents MUST be clearly referred to)
5.1 Please list out relevant international guidelines and their summaries
e.g.  The new drug has been recommended in the US guidelines (American College 
of Cardiology Foundation / American heart Association Take Force on Practice 
Guidelines) as an alternative to warfarin for the prevention of stroke and 
systemic thromboembolsim in patients with paroxysmal to permanent AF and 
risk factors for stroke or systemic embolisation who do not have a prosthetic 
heart valve or haemodynamically significant valve disease, severe renal failures 
(CrCL<15 ml/min), or advanced liver disease (impaired baseline clotting 
function).
5.2  Please indicate if this new drug has been evaluated by Australia 
Pharmaceutical Benefits Scheme (PBS), UK National Institute of Clinical 
Excellence (NICE), Scottish Medicines Consortium (SMC), and their 
recommendation(s)
5.2.1 PBS: e.g.  not listed in PBS
5.2.2 NICE: e.g.  under review
5.2.3 SMC: e.g.  accepted for use as first-line treatment in patients with locally 
advanced or metastatic non-small cell lung cancer with 
epidermal growth factor receptor activating mutations.
6.  COST COMPARISON AND BUDGET IMPACT
6.1  Cost comparison of this new drug with existing alternatives in HADF 
as listed in 2.4.1
HADF 
status
Drug Strength Unit cost 
$
Dose regimen
(also provide 
maximum 
maintenance 
dose)
Daily 
cost/cost 
per cycle
Annual/
Treatment 
cost $
New Drug e.g. (1) 
150mg
$520 50mg once 
daily continuous 
till remission/
progression/
lifetime
Max 50mg once 
daily
$520/day Annual cost 
$189,800
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HADF 
status
Drug Strength Unit cost 
$
Dose regimen
(also provide 
maximum 
maintenance 
dose)
Daily 
cost/cost 
per cycle
Annual/
Treatment 
cost $
e.g. (2) 
50mg
$8400/
vial
e.g. 50mg/m2  
i.v. on day 1 every 
3 week, rest 1 
week, then repeat; 
max 75mg/m2 for 
8 cycles
$16,800/
cycle
Max 
$25,200
(@1.6m2)
Total 
treatment 
cost for 
8 cycles 
$134,400
Max 
$201,600
e.g. (3) 
50mg
$8400/
vial
e.g. 70mg/m2  
s.c. every 2 
weeks; max 
100mg, for 6 
months
$25,200/ 
2 weeks
Max 
$33,600/ 
2 weeks
(@1.6m2)
Total 
treatment 
cost for 
6 months 
$302,400
Max 
$403,200
G/S/SFI/
SN
Alternative 
G/S/SFI/
SN
Alternative 
G/S/SFI/
SN
Alternative 
G/S/SFI/
SN
Alternative 
6.2 Budget impact
(1)  Prevalence data (1)  Total no. of patients with this disease in HK = e.g. 200,000
(2)  Total no. of patients with this disease in HA = e.g. 100,000
(3)   Total no. of patients in HA who fulfil the proposed HADF 
indication as stated in Section 2.7 = e.g. 6,000
(4)  Total no. of NEW patients in HA who fulfil the proposed HADF 
indication as stated in Section 2.7 = e.g. 800
(5)  Data source (Please state how this is estimated e.g. patient 
registry, CDARS, recommendation from HADF Expert Panel) : 
 e.g.  Cancer registry 2012
(2)  Tota l  budget 
i m p a c t  p e r 
annum in HA
(Please indicate if there is any increase in patient no. in the next 
few years)
e.g.  Year 1 = 6,000 (backlog) +  800 (NEW) = 6,800  
Year 2 = 6,800 + 800 – 200 (withdrawal/progression) = 
7,400
(3)  Possible cost 
saving
(1)  Replacement of existing option(s) as stated in Section 2.4 
(please list out) =  
(2)  Other resource(s) = (e.g. lab, shorten hospitalisation, delay of 
surgery etc.)  
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7. SUPPORTING DOCUMENTS FOR THIS SUBMISSION 
Please submit the following documents for evaluation   
(in hard and soft copies)
(1) Prescribing information sheet (package insert)
(2) Supporting references for sections 1 – 6 where applicable
 *  List out the references under this section
 *  Please ensure that all supporting documents are clearly numbered and 
referred to 
 *  Provide soft copy of the references in PDF format and the full reference list in 
Microsoft word 
References:
8.  CHAIRPERSON OF THE DRUG AND THERAPEUTICS COMMITTEE
Name:
Designation:
Signature:
Date:
